Actively Recruiting
Cognitive Screening in Lung Cancer Patients
Led by European Institute of Oncology · Updated on 2024-12-10
200
Participants Needed
1
Research Sites
103 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to investigate the occurrence of cancer and adjuvant therapy-related cognitive impairment in patients with both NSCLC and SCLC. The primary endpoint measure will be the presence of cognitive impairment during the first year after enrollment through the administration of a comprehensive neuropsychological assessment.
CONDITIONS
Official Title
Cognitive Screening in Lung Cancer Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with small-cell or non-small-cell lung cancer at any stage (I, II, III, IV)
- Age 18 years or older
- Able to speak and read the local language fluently
- Provided informed consent by signing the consent form
You will not qualify if you...
- Age 70 years or older
- Presence of brain metastases
- Having neurological or psychiatric disorders
- Undergoing brain radiotherapy
- Previous diagnosis of lung cancer
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Istituto Europeo di Oncologia
Milan, Italy, 20141
Actively Recruiting
Research Team
G
Gabriella Pravettoni
CONTACT
L
Lorenzo Conti
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here